Cargando…

Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.

Immune checkpoint inhibitors (ICIs) as monotherapy in different solid tumors showed an early detrimental effect in a subset of patients reflected by the early crossover of the progression-free survival (PFS) curves. Currently, combination therapies with ICIs added to chemotherapy or targeted therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carretero-González, Alberto, Otero, Irene, Lora, David, Carril-Ajuria, Lucía, Castellano, Daniel, de Velasco, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906255/ https://www.ncbi.nlm.nih.gov/pubmed/33680572 http://dx.doi.org/10.1080/2162402X.2021.1878599

Ejemplares similares

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2018)

Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2019)

The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
por: Carretero-González, Alberto, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
por: Manneh, Ray, et al.
Publicado: (2022)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
por: Zhang, Yiru, et al.
Publicado: (2023)

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
por: Carril-Ajuria, Lucía, et al.
Publicado: (2019)

A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial
por: de Velasco, Guillermo, et al.
Publicado: (2020)

Addendum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial
por: de Velasco, Guillermo, et al.
Publicado: (2022)

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
por: Liu, Qingyan, et al.
Publicado: (2023)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis
por: Zeng, Yi-Fan, et al.
Publicado: (2023)

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
por: Mo, Dun-Chang, et al.
Publicado: (2022)

The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
por: Zhang, Tengfei, et al.
Publicado: (2016)

Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers
por: Al-Showbaki, Laith, et al.
Publicado: (2021)

Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
por: Li, Yuegang, et al.
Publicado: (2022)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
por: You, Wei, et al.
Publicado: (2018)

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
por: Tang, Hui, et al.
Publicado: (2022)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
por: Ma, Long, et al.
Publicado: (2021)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
por: Mishra, Surbhi, et al.
Publicado: (2022)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
por: Zhao, Yating, et al.
Publicado: (2021)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
por: Zhong, Liting, et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
por: D’Alterio, Crescenzo, et al.
Publicado: (2019)

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities
por: Costa, Ricardo, et al.
Publicado: (2017)

The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiao-Jiang, et al.
Publicado: (2020)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
por: Yang, Li, et al.
Publicado: (2020)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
por: Boustani, Jihane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_14hp9hd2uo10h4q94l4pr4gueq